Medical Use
RETEVMO® is a kinase inhibitor indicated for the treatment of: metastatic non-small cell lung cancer (NSCLC), Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, and metastatic solid tumors.
Warning & Precautions
Warning and Precautions
-
Hepatotoxicity: Monitor ALT/AST regularly; withhold, reduce, or discontinue based on severity.
-
Interstitial Lung Disease/Pneumonitis: Watch for pulmonary symptoms; adjust or stop treatment as needed.
-
Hypertension: Control BP before starting; monitor regularly; withhold, reduce, or discontinue if severe.
-
QT Prolongation: Monitor QT interval, electrolytes, TSH; adjust or discontinue if prolonged.
-
Hemorrhage: Permanently discontinue if severe or life-threatening bleeding occurs.
-
Hypersensitivity: Withhold, treat with corticosteroids, then resume at reduced dose with gradual escalation.
-
Tumor Lysis Syndrome: Monitor high-risk patients closely and treat as indicated.
-
Wound Healing: Withhold ≥7 days before elective surgery; avoid for ≥2 weeks post-surgery until healed.
-
Hypothyroidism: Monitor thyroid function; withhold or discontinue if severe.
-
Embryo-Fetal Toxicity: Can harm fetus; advise effective contraception for females of reproductive potential.
Documentation Availability
Documentation & Availability:
- Documents required to import RETEVMO® (selpercatinib) to India?
RETEVMO® (selpercatinib) can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- 2 ID proofs along with PAN card details along with attested scanned copies
- Valid doctor prescription scanned copy
- Patient’s diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- The above-mentioned documents and drug availability.
- Import permit if applicable.
Sourcing & Delivery
Sourcing & Delivery:
The Rx4U team has extensive experience in sourcing selpercatinib metastatic non-small cell lung cancer (NSCLC), metastatic thyroid cancer, metastatic solid tumors) around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
FAQ:
What is the Generic Name for the trade name drug Retevmo?
The generic name for Retevmo is selpercatinib.
Who manufactures RETEVMO® (selpercatinib)?
RETEVMO® (selpercatinib) is manufactured by Eli Lilly and Company.
Is RETEVMO® (selpercatinib) FDA approved?
Yes, Retevmo was approved by the FDA in 2020.
What is the dosage and form of RETEVMO® (selpercatinib)?
RETEVMO® (selpercatinib) is available in tablets form, with dosages of 40 mg and 80 mg for oral administration.
How to order RETEVMO® (selpercatinib) online in India?
RETEVMO® (selpercatinib) can be ordered online in India through https://rx4u.in/.
